A process for the preparation of N-(amino-4,6-dihalopyrimidine)formamides of the formula: ##STR1##
in which X is a halogen atom, starting from 2,5-diamino-4,6-dihalopyrimidine of the formula: ##STR2##
in which X has the meaning afore-mentioned, by reaction with formic acid.
|
1. A process for the preparation of N-(amino-4,6-dihalopyrimidine)formamides of the formula: ##STR7##
in which X is a halogen atom, comprising reacting a 2,5-diamino-4,6-dihalopyrimidine of the formula: ##STR8## in which X has the meaning mentioned above, with formic acid of sufficient strength to produce the N-(amino-4,6-dihalopyrimidine)formamide of formula I or with formic acid of sufficient strength to produce the N-(amino-4,6-dihalopyrimidine)formamide of formula II. 2. The process according to
3. The process according to
4. The process according to
comprising reacting a 2,5-diamino-4,6-dihydroxy-pyrimidine or a salt thereof of the formula: ##STR10## with a phosphorus oxyhalide and a quaternary ammonium halide or a tertiary amine or a salt of said amine in a halogenated hydrocarbon as a solvent. 5. The process according to
7. The process according to
comprising reacting a 2,5-diamino-4,6-dihydroxy-pyrimidine or a salt thereof of the formula: ##STR12## with a phosphorus oxyhalide and a quaternary ammonium halide or a tertiary amine or a salt of said amine in a halogenated hydrocarbon as a solvent. 8. The process according to
12. The process according to
13. The process according to
comprising reacting a 2,5-diamino-4,6-dihydroxypyrimidine or a salt thereof of the formula: ##STR14## with a phosphorus oxyhalide and a quaternary ammonium halide or a tertiary amine or a salt of said amine in a halogenated hydrocarbon as a solvent. |
This application claims benefit of U.S. Provisional application Ser. No. 60/146,106 filed on Jul. 29, 1999.
1. Field of the Invention
The invention relates to a novel process for the preparation of N-(amino-4,6-dihalopyrimidine)-formamides of the formula ##STR3##
starting from a 2,5-diamino-4,6-dihalopyrimidine of the general formula ##STR4##
2. Back of the Invention
N-(Amino-4,6-dihalopyrimidine)formamides such as N-(2-amino-4,6-dihalopyrimidin-5-yl)formamide are important intermediates for the production of antiviral nucleotide derivatives (EP-A 0 684 236).
To date, a number of processes for the preparation of N-(2-amino-4,6-dihalopyrimidin-5-yl)formamide have been disclosed. Thus EP-A 0 684 236, for example, describes a process for the preparation of N-(2-amino-4,6-dihalopyrimidin-5-yl)formamide starting from an aminomalonic ester. In this process, the aminomalonic ester is first cyclized to 2,5-diamino-4,6-dihydroxypyrimidine with guanidine in the presence of an alkoxide and then 4,6-dichloro-N'-(dimethylaminomethylene)pyrimidine-2,5-diamine is formed from this with phosphorus oxychloride in the presence of dimethylformamide. The latter is subsequently converted into the desired product using aqueous propionic acid.
The disadvantages of this process are, on the one hand, the moderate yield of desired product and, on the other hand, the fact that this process proceeds via 3 stages.
To date, a number of processes for the preparation of 2,5-diamino-4,6-dihalopyrimidines such as 2,5-diamino-4,6-dichloropyrimidine have also been disclosed. For example, WO 91/01310 describes a process for the preparation of 2,5-diamino-4,6-dichloropyrimidine starting from 2,5-diamino-4,6-dihydroxypyrimidine in the presence of phosphorus oxychloride and a quaternary ammonium halide or a weakly basic tertiary amine or its salt. In this process, the phosphorus oxychloride serves as a solvent.
This process has the disadvantage that it is not reproducible on the industrial scale and the desired final product is only obtained in low yield.
The object of the present invention was to make available a simpler process for the preparation of N-(amino-4,6-dihalopyrimidine)formamides, in which the desired product is obtained in good yield.
Surprisingly, it has now been found that if a 2,5-diamino-4,6-dihalopyrimidine of the general formula ##STR5##
in which X is a halogen atom is reacted with formic acid, the final products of the general formula I or II are obtained directly, i.e. without intermediates, in excellent yield.
Cl or Br can be employed as the halogen atom, preferably Cl is employed. Accordingly, 2,5-diamino-4,6-dichloro- or 2,5-diamino-4,6-dibromopyrimidine is preferably employed as the 2,5-diamino-4,6-dihalopyrimidine.
The formic acid employed below is at least 70-98% strength formic acid.
Expediently, if the preparation of the product of the formula I is desired, a 70-80% strength formic acid is employed and the reaction is carried out at a temperature of 20°C to 60°C, preferably of 25°C to 55°C
If the preparation of the product of the formula II is desired, expediently an 80-98% strength formic acid is employed and the reaction is carried out at a temperature of 0°C to 30°C, preferably of 10° to 25°C
Surprisingly, it has also been found that the starting material 2,5-diamino-4,6-dihalopyrimidine of the general formula III is obtained in good yield if 2,5-diamino-4,6-dihydroxypyrimidine or its salt of the formula ##STR6##
is reacted with a halogenated hydrocarbon as a solvent in the presence of a phosphorus oxyhalide and a quaternary ammonium halide or a tertiary amine.
2,5-Diamino-4,6-dihydroxypyrimidine is a commercially available compound. A suitable 2,5-diamino-4,6-dihydroxypyrimidine is also its salts such as its hydrohalide salts such as the hydrochloride salts and hydrobromide salts.
The phosphorus oxyhalide employed is expediently phosphorus oxychloride or phosphorus oxybromide.
The amine used can be a tertiary amine or its salts such as its hydrochloride or hydrobromide salts. The quaternary ammonium halide employed is expediently ammonium chloride or ammonium bromide. Customarily, the amine or the quaternary ammonium halide is employed in an excess based on the 2,5-diamino-4,6-dihydroxypyrimidine, preferably 1 to 10 mol of amine are employed based on 1 mol of 2,5-diamino-4,6-dihydroxypyrimidine.
The reaction is expediently carried out at a temperature of 20°C up to the reflux temperature of the appropriate solvent, preferably of 100° to 120°C
The halogenated hydrocarbons used can be halogenated aliphatic hydrocarbons. Examples of halogenated aliphatic hydrocarbons are halogenated alkanes. The halogenated alkane employed can be a halogenated propane such as 1,2,3-trichloropropane.
Preparation of 2,5-diamino-4,6-dichloropyrimidine
2,5-Diamino-4,6-dihydroxypyrimidine hydrochloride (0.14 mol, 25 g) was filled into a dry reactor. Dry 1,2,3-trichloropropane (51.96 ml) was then added and the whole was stirred. Subsequently, tetramethylammonium chloride (0.29 mol, 31.25 g) and then POCl3 (0.54-0.81 mol, 124.9-83.28 g, 50.6-75.9 ml) were added. The reaction was heated at reflux temperature (about 115°C) for 24 h. The reaction was then cooled to below 50°C, ice water (24.44 mol, 440.44 g) was added and the whole was kept below 55°C Subsequently, the reaction was adjusted to a pH of between 6.5 and 7.0 using 50% strength NaOH (3.12 mol, 124.92 g, 163.3 ml) and the temperature was kept below 55°C The reaction was stirred at between 50 and 60°C for 30 min. Tetrahydrofuran (3.7 mol, 267.0 g, 300 ml) was then added. In order to remove undesired material, the whole mixture was filtered through Celite and the filter cake was then washed with ethyl acetate (20.5 mol, 1806.58 g, 2002.86 ml) for subsequent extraction. The organic phase (tetrahydrofuran and ethyl acetate) was washed 3 times with water (5.57 mol, 100.32 g, 100.32 1), dried over NaHCO3 and filtered. Ethyl acetate was removed by vacuum distillation. Hexane (0.77 mol, 66.14 g, 100.36 ml) was then added to the residual organic material, and the whole was cooled to below 10° C., filtered and then dried at 50°C in vacuo. The title product (0.09 mol, 15.71 g) was obtained as a slightly brownish solid, corresponding to a yield of about 65% based on 2,5-diamino-4,6-dihydroxypyrimidine employed.
Preparation of N-(2-amino-4,6-dichloropyrimidin-5-yl)-formamide
2,5-Diamino-4,6-dichloropyrimidine (0.01 mol; 2.0 g) and water (0.25 mol; 4.55 ml) were stirred at room temperature. 98% strength formic acid (0.4 mol; 18.27 g; 14.97 ml) was then added to the reaction. The reaction was subsequently heated to 50-55°C and kept at this temperature for 3 h.
Toluene (0.38 mol; 34.6 g; 40 ml) was then added for the azeotropic distillation under high vacuum at 50°C (toluene was added twice to guarantee a good distillation, i.e. a total of 80 ml).
The product was subsequently filtered, washed with water and then dried at 60°C in vacuo. 0.01 mol (2.0 g) of the abovementioned product was obtained, corresponding to a yield of about 90%.
Preparation of N-(5-amino-4,6-dichloropyrimidin-2-yl)-formamide
A solution of 2,5-diamino-4,6-dichloropyrimidine (0.001 mol; 2.0 g) and 98% strength formic acid (0.5 mol, 22.96 g, 18.8 ml) was stirred overnight at room temperature. Toluene (0.94 mol, 86.76 g, 18.82 ml) was then added and the reaction was cooled to 0°-5°C
The product was filtered off and washed with water (1.11 mol, 20.0 g, 20.0 ml). The product was subsequently dried at 50°C in vacuo. N-(5-Amino-4,6-dichloropyrimidin-2-yl)formamide was detected in the 1 H NMR as a single product. 0.01 mol (1.62 g) of the abovementioned product was obtained, corresponding to a yield of about 70%.
Saikali, Elie, Brieden, Walter
Patent | Priority | Assignee | Title |
7208596, | Nov 25 2003 | BRISTOL-MYERS SQUIB PHARMA COMPANY; Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
7442792, | Nov 25 2003 | Bristol-Myers Squibb Pharma Company | Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
8883798, | Feb 28 2011 | USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V V I ; USTAV EXPERIMENTALNI MEDICINY AKADEMIE VED CR, V V I | Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof |
Patent | Priority | Assignee | Title |
4965270, | Dec 11 1986 | Novartis International Pharmaceutical Ltd | Purine derivatives |
5583226, | Apr 27 1994 | Lonza AG | 4,6-dichloropyrimidine and related compounds |
EP684236, | |||
WO9101310, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Dec 16 1999 | Lonza AG | (assignment on the face of the patent) | / | |||
Jan 19 2000 | SAIKALI, ELIE | Lonza AG | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010552 | /0221 | |
Jan 19 2000 | BRIEDEN, WALTER | Lonza AG | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010552 | /0221 |
Date | Maintenance Fee Events |
Aug 29 2001 | ASPN: Payor Number Assigned. |
Jan 06 2004 | ASPN: Payor Number Assigned. |
Jan 06 2004 | RMPN: Payer Number De-assigned. |
Jan 30 2005 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Dec 16 2008 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Mar 20 2013 | REM: Maintenance Fee Reminder Mailed. |
Aug 07 2013 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Aug 07 2004 | 4 years fee payment window open |
Feb 07 2005 | 6 months grace period start (w surcharge) |
Aug 07 2005 | patent expiry (for year 4) |
Aug 07 2007 | 2 years to revive unintentionally abandoned end. (for year 4) |
Aug 07 2008 | 8 years fee payment window open |
Feb 07 2009 | 6 months grace period start (w surcharge) |
Aug 07 2009 | patent expiry (for year 8) |
Aug 07 2011 | 2 years to revive unintentionally abandoned end. (for year 8) |
Aug 07 2012 | 12 years fee payment window open |
Feb 07 2013 | 6 months grace period start (w surcharge) |
Aug 07 2013 | patent expiry (for year 12) |
Aug 07 2015 | 2 years to revive unintentionally abandoned end. (for year 12) |